ArticlePloS one2011
Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 84 citations in OpenAlex.
- Impaired Antibody-Independent Immune Response of B Cells in Patients With Acute Dengue Infection.Frontiers in immunology · 2019Trial
- Quantitative and qualitative differences in anti-Envelope IgG-secreting cells distinguish subclinical and hospitalized dengue in a Cambodian pediatric cohort.PLoS pathogens · 2026Article
- Polyclonal antibodies and probiotics improve immune dysfunction in a mouse model of inflammatory bowel disease.Scientific reports · 2026Article
- Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026Review
- CD4Vaccines · 2025Article
- Article
- COVID-19 vaccination induces cross-reactive dengue virus antibodies with altered isotype profiles andFrontiers in immunology · 2025Article
- Plasma cells are not restricted to the CD27+ phenotype: characterization of CD27-CD43+ antibody-secreting cells.Frontiers in immunology · 2023Article
- Temporal patterns of functional anti-dengue antibodies in dengue infected individuals with different disease outcome or infection history.Scientific reports · 2022Article
- Infection order outweighs the role of CD4iScience · 2022Article
- Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19.Frontiers in immunology · 2022Review
- Plasmablast Expansion Following the Tetravalent, Live-Attenuated Dengue Vaccine Butantan-DV in DENV-Naïve and DENV-Exposed Individuals in a Brazilian Cohort.Frontiers in immunology · 2022Article
- Immunophenotyping and Transcriptional Profiling of Human Plasmablasts in Dengue.Journal of virology · 2021Article
- The immunodominant antibody response to Zika virus NS1 protein is characterized by cross-reactivity to self.The Journal of experimental medicine · 2021Article
- Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection.Cell reports. Medicine · 2021Article
- Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.The journal of gene medicine · 2021Article
- Article
- Robust Plasma Cell Response to Skin-Inoculated Dengue Virus in Mice.Journal of immunology research · 2021Article
- Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell generation in patients with acute COVID-19.Clinical & translational immunology · 2021Article
- Autoantibody Profiling in Plasma of Dengue Virus-Infected Individuals.Pathogens (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDengue virus is transmitted by mosquitoes and has four serotypes. Cross-protection to other serotypes lasting for a few months is observed following infection with one serotype. There is evidence that low-affinity T and/or B cells from primary infections contribute to the severe syndromes often associated with secondary dengue infections. such pronounced immune-mediated enhancement suggests a dengue-specific pattern of immune cell activation. This study investigates the acute and early convalescent B cell response leading to the generation of cross-reactive and neutralizing antibodies following dengue infection. METHODOLOGY/PRINCIPAL
findingsWe assayed blood samples taken from dengue patients with primary or secondary infection during acute disease and convalescence and compared them to samples from patients presenting with non-dengue related fever. Dengue induced massive early plasmablast formation, which correlated with the appearance of polyclonal, cross-reactive IgG for both primary and secondary infection. Surprisingly, the contribution of IgG to the neutralizing titer 4-7 days after fever onset was more than 50% even after primary infection. CONCLUSIONS/SIGNIFICANCE: Poly-reactive and virus serotype cross-reactive IgG are an important component of the innate response in humans during both primary and secondary dengue infection, and "innate specificities" seem to constitute part of the adaptive response in dengue. While of potential importance for protection during secondary infection, cross-reactive B cells will also compete with highly neutralizing B cells and possibly interfere with their development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.